From f68030892f743ca7bf2ae061138ee07e108f963d Mon Sep 17 00:00:00 2001
From: Kaya <kaya.lange@uni-bielefeld.de>
Date: Mon, 2 Dec 2024 12:16:35 +0100
Subject: [PATCH] changes team
---
src/contents/team.tsx | 2 +-
src/data/hptimelinedata.tsx | 5 ++--
src/data/steckbriefe.ts | 48 +++----------------------------------
3 files changed, 6 insertions(+), 49 deletions(-)
diff --git a/src/contents/team.tsx b/src/contents/team.tsx
index 621f94a0..65a0da61 100644
--- a/src/contents/team.tsx
+++ b/src/contents/team.tsx
@@ -109,7 +109,7 @@ function createSteckbriefe(data: Array<SteckbriefInterface>){
let picture = <div className="col-2 lnp center"><img src={data[index].zweitfoto} style={{display: "none"}} className={"img team-img side-margins-auto "+backbriefclass}/><img src={data[index].hauptfoto} className={"img team-img "+frontbriefclass}></img></div>
let namerow = <div className="row"><div className="team-name"> {title} {data[index].vorname} {data[index].nachname} <span className="pronouns"> ({data[index].pronouns}) </span> </div> <div className="col"> <a href={data[index].linkedinurl}> <img className="team-socials" src="https://static.igem.wiki/teams/5247/design/icons/linkedin.png" /> </a></div> </div>;
- let frontparagraph = <div className={"row " + frontbriefclass}> <h6>Why I took part in iGEM</h6> {why} </div> ;
+ let frontparagraph = <div className={"row " + frontbriefclass}> <h6>Why I took part in iGEM ?</h6> {why} </div> ;
let facts = <div className={frontbriefclass}><div className=""> <b>Age:</b> {data[index].age} </div> <br/> {headof} <div> <b>Part of:</b> {jobs}</div> <br/> <div className=""> <b>Major:</b> {data[index].studiengang} </div> <br/> <div className=""> <b>Scientific interests:</b> {data[index].scientificinterests} </div> </div>;
let backbutton = <div className={backbriefclass} style={{display: "none"}}> <div className="parent-button"><button onClick={flipBack(thename)} className="frontbutton">Click me</button></div></div>
let funfactlist = <div className={backbriefclass} style={{display: "none"}}><b>Funfacts: </b><ul> {funfacts}</ul></div>
diff --git a/src/data/hptimelinedata.tsx b/src/data/hptimelinedata.tsx
index ca876abb..6293513a 100644
--- a/src/data/hptimelinedata.tsx
+++ b/src/data/hptimelinedata.tsx
@@ -249,7 +249,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
“How positively and calmly Max deals with his illness but has also pointed out that he is lucky, and that other people are much worse off - how much you have to pay attention to little things that you wouldn't have expected as a healthy person.†</p>
</>],
implementation: [<> <p>This most important aspect of this meeting was less an insight, but the fact Max helped us to put a face to an abstract idea. Many of our ideas to treat CF were interesting and adventurous but meeting him put a lot into perspective. </p>
- <p>Max played a significant role in shaping our project from the outset, particularly in guiding our focus on <OurLink path='judging' scrollTo='best-integrated-human-practice' text='Integrated Human Practices'/> and Safety & Security {/*safety-security [Link Best Biosafety] */}as special prizes. Through our discussions, we recognized the importance of these aspects in developing the best possible cure. This collaborative effort led us to pivot our target from the pancreas to the lung and move away from a diagnostic approach. His contributions not only provided valuable insights but also fostered a strong personal investment in our project.</p></>],
+ <p>Max played a significant role in shaping our project from the outset, particularly in guiding our focus on <OurLink path='judging' scrollToID='best-integrated-human-practice' text='Integrated Human Practices'/> and Safety & Security {/*safety-security [Link Best Biosafety] */}as special prizes. Through our discussions, we recognized the importance of these aspects in developing the best possible cure. This collaborative effort led us to pivot our target from the pancreas to the lung and move away from a diagnostic approach. His contributions not only provided valuable insights but also fostered a strong personal investment in our project.</p></>],
pictureurl_implementation: "",
interview: <><QaBox q="How and when were you first diagnosed? " a="When I was about one year old. My mother did not do any screenings or prenatal testing. I was in pain but as an infant you cannot say that, so I screamed a lot. Many doctors shrug that off in small children but after some time a sweat test was done at the children's clinic." />
<QaBox q="What do you think about diagnosing via sweat tests?" a="I am a clear opponent of diagnosing via sweat tests, especially if it is used to rule out CF and people have atypical CF, because of which they do not get diagnosed because of that." />
@@ -322,7 +322,6 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
tag: "Academia",
heading: "Discussion about the delivery method- AVV vs. LNPs and prime editing and gene therapy innovations",
interviewtabid: "kristian",
-
language: "de",
quoteNachname: " Müller, Reasearch Expert for Gene Therapy ",
quoteVorname: "Prof. Dr. Kristiann",
@@ -333,7 +332,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
AAVs are a well-established vehicle in gene therapy, having been used successfully in various approved treatments. They are highly efficient at delivering genetic material to target cells, especially in well-characterized diseases like CF. One of their key strengths is their ability to precisely target specific tissues, making them particularly valuable for lung delivery in Cystic Fibrosis. However, AAVs come with notable challenges, primarily their limited packaging capacity (approximately 4.5 kilobases), which constrains the size of the genetic payload they can carry. Additionally, AAVs can elicit immune responses, particularly when multiple doses are required, posing a barrier to their long-term use.
On the other hand, LNPs offer a scalable and re-dosable alternative. LNPs have the advantage of a larger packaging capacity, allowing them to carry more complex genetic instructions or larger gene-editing tools, such as prime editors. They are also easier and cheaper to produce on a large scale, making them an attractive option for widespread clinical applications. A significant benefit of LNPs is their lower immunogenicity, which reduces the risk of adverse immune reactions upon repeated dosing. However, LNPs currently face challenges in specific targeting compared to AAVs. AAVs have a higher precision in targeting specific tissues, while LNPs still need optimization for targeted delivery to areas like the lungs.</p>],
implementation: [<p>Prof. Müller’s insights directly inform the implementation of our iGEM project, where we aim to design novel prime editors that are small enough to be delivered efficiently, while also exploring LNPs{/* [LINK Cycle Delivery] */} as a scalable and re-dosable alternative to AAVs. By tailoring our approach to address the specific challenges of CF, such as mucus penetration and lung cell targeting, we can enhance the precision and efficacy of gene therapy. These innovations have the potential to set new standards in the field and contribute to broader research on genetic disease treatment.</p>],
- summary: "In our interview with Prof. Dr. Kristian Müller, we explored the revolutionary potential of prime editing as a next-generation gene editing technology. Prof. Müller highlighted the advantages of prime editing over traditional CRISPR-Cas systems, particularly its ability to make precise genetic modifications without double-strand breaks, thus reducing off-target effects. He emphasized the importance of optimizing delivery systems, such as AAV and LNPs, and discussed the ethical considerations and biosafety measures crucial for advancing gene therapy. The interview underscored the significance of Cystic Fibrosis as a model disease, given its prevalence and the potential for impactful treatments through targeted genetic corrections.",
+ summary: [<p>In our interview with Prof. Dr. Kristian Müller, we explored the revolutionary potential of prime editing as a next-generation gene editing technology. Prof. Müller highlighted the advantages of prime editing over traditional CRISPR-Cas systems, particularly its ability to make precise genetic modifications without double-strand breaks, thus reducing off-target effects. He emphasized the importance of optimizing delivery systems, such as <OurLink path='engineering?tab=delivery' tabID='delivery' text="AAV and LNPs"/>, and discussed the ethical considerations and biosafety measures crucial for advancing gene therapy. The interview underscored the significance of Cystic Fibrosis as a model disease, given its prevalence and the potential for impactful treatments through targeted genetic corrections.</p>],
months: "April",
interview:<><iframe title="Bielefeld-CeBiTec: Interview Müller AAV vs LNP (2024) [English]" width="560" height="315" src="https://video.igem.org/videos/embed/0613b6b8-7755-4373-9d86-9910fe30781f" frameBorder="0" allowFullScreen={true} sandbox="allow-same-origin allow-scripts allow-popups allow-forms"></iframe><p>This interview was recorded on video at a later date.</p></>,
},
diff --git a/src/data/steckbriefe.ts b/src/data/steckbriefe.ts
index 8ccc050c..047c60b1 100644
--- a/src/data/steckbriefe.ts
+++ b/src/data/steckbriefe.ts
@@ -356,11 +356,11 @@ export const teammembers: Array<SteckbriefInterface> = [
],
bestpart: [
- "Learning a lot about scientific research, handling stress and working in the lab",
- "Working in a team, implementing a large and significant project together to achieve our goal",
+ "Learning a lot about scientific research, handling stress and working in the lab.",
+ "Working in a team, implementing a large and significant project together to achieve our goal.",
],
biggestchallenge: [
- "The biggest challenge is time management, beacuse it is quite difficult to manage all the different aspects of the project"
+ "The biggest challenge is time management, beacuse it is quite difficult to manage all the different aspects of the project."
],
funfacts: [
"I tend to say yes to everything",
@@ -649,48 +649,6 @@ export const teammembers: Array<SteckbriefInterface> = [
scientificinterests: "Algae & Microbiology, OMICs and Systems Biology",
},
- {
- vorname: "Vincent Carl",
- nachname: "Stöckl",
- age: "20",
- hauptfoto: "https://static.igem.wiki/teams/5247/photos/team-photos/vincent-1-1-11zon.webp",
- zweitfoto: "https://static.igem.wiki/teams/5247/photos/team-photos/vincent-2-2-11zon.webp",
- pronouns: "he/him",
- studiengang: "B.Sc. Molecular Biotechnology",
- igemjob: ["Sponsoring"],
- whyigem: [
- "a chance to work as a real scientist as well as being part of a team working at the cutting edge of biotechnology",
- "this is a unique opportunity to become an active part of a team of (student) scientits who are collaborating in a high profile scientific project with studenta ranging from 3rd semester to the one's who are currently involved in their master's",
- ],
- bestpart: [
- "The challenge of trying new things and working as a real scientist",
- ],
- biggestchallenge: [
- "balancing iGEM and university work",
- ],
- funfacts: [
- "no fun facts",
- ],
- favlabmusic: "Techno workout playlist from Lisa",
- islands: [
- "a pocket knive",
- "sunscreen",
- "water",
- ],
- onechange: [
- "Make it more accesseble to people from all walks of life",
- ],
- hobbies: [
- "Medieval Reenactment",
- "sword Fighting",
- "gun club",
- "friends",
- "painting",
- "drawing",
- ],
- scientificinterests: "Phytomining and Remediation and Synthetic Organs/ Limbs",
- },
-
]
export const advisors: Array<SteckbriefInterface> = [
--
GitLab